ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GSK Gsk Plc

1,660.80
0.00 (0.00%)
19 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 1,660.80 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
1,661.00 1,661.60
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.88 68.39B
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 1,660.80 GBX

Gsk (GSK) Latest News

Gsk (GSK) Discussions and Chat

Gsk (GSK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2024-03-18 17:30:521,652.64811,338.64O
2024-03-18 17:30:271,659.0047779.73O
2024-03-18 17:29:321,654.797,350121,626.84O
2024-03-18 17:29:321,646.5950823.30O
2024-03-18 17:28:101,652.699148.74O

Gsk (GSK) Top Chat Posts

Top Posts
Posted at 18/3/2024 08:20 by Gsk Daily Update
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,649.60p.
Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £68,392,159,472.
Gsk has a price to earnings ratio (PE ratio) of 13.88.
This morning GSK shares opened at 1,656.40p
Posted at 04/3/2024 07:46 by pj84
JOHCM’s Costar views GSK as a good pick
GSK (GSK) is ‘attractively valued’ versus its pharmaceutical peers even though it has addressed profitability concerns, says JOHCM manager Mark Costar.

The Citywire Elite Companies AAA-rated stock is the second-largest holding in the JOHCM UK Dynamic fund, where it makes up 5.5% of the £1bn portfolio. Costar took over the running of the fund in January following the departure of Alex Savvides who left for Jupiter.

GSK was the second-largest contributor to returns in January after it reported ‘an encouraging set of full-year 2023 annual results while upgrading long-term growth guidance’.

It also addressed concerns about the ‘patent loss cliff edge’ suffered by its Dolutegravir HIV treatment and ‘its potential impacts on future profitability’.

‘Encouragingly, the fourth-quarter dividend was also increased, a step towards better shareholder returns where the fund has been engaged,’ said Costar.

‘The shares remain attractively valued versus peers, with further positive runway should a resolution to the Zantac case materialise.’

The shares softened 0.2% to £16.62 on Friday.
Posted at 13/2/2024 10:09 by tradermichael
The healthcare team at Citi has turned positive on GSK PLC (LSE:GSK, NYSE:GSK) for the first time in seven years.

Pushing the investment bank's analysts over the precipice to 'buy' was the outlook for belantamab mafodotin, (known as Blenrep for short), the drug giant's treatment for the blood disease myeloma.

"Our upgrade is based not only on Blenrep’s underappreciated revenue potential but also the cumulative impact of the multiple incremental positives ranging from Zantac liability outlook, RSV/ Shingrix, astute business development, and increasingly positive ViiV outlook post dolutegravir loss of exclusivity," Citi said in a note to clients.

Its upbeat stance on Blenrep stems from the "compelling" results from GSK's DREAMM-7 phase III clinical trial. Assuming the next set of study results are positive, then the drug "has a significant role for at least the next five years as a standard of care for refractory myeloma patients, particularly for older patients that are either poor candidates for CAR-T or bispecifics, or who receive their treatment within the community".

In early trade, the shares were up 14.34p at 1,640.74p. Citi reckons the stock is worth £21 (up from £17).
Posted at 07/2/2024 21:09 by pj84
From yesterdays questor column

"GSK is performing well despite the legal clouds that hang over it
Questor share tip: more of its vaccines are proving their worth and the company’s valuation fails to reflect punchy growth forecasts

Russ Mould

6 February 2024 • 6:00am

Strong full-year numbers last week, a planned dividend rise in 2024 and upgraded medium-term growth and profit forecasts all support our confidence in GSK, where a blossoming drugs pipeline gives additional visibility and increases the chances of some reward for readers in the form of both capital appreciation and income.

A fourth dismissal or settlement of lawsuits relating to the heartburn treatment Zantac is also encouraging.

While the legal cloud regarding the drug and its allegedly carcinogenic side-effects is far from fully lifted, the market’s worst fears regarding possible liabilities are yet to be borne out and the shares still trade some 9pc below highs reached almost two years ago.

GSK still faces a lengthy list of cases, but the more that are settled, the greater the chance that investors can again focus on the day-to-day business, which is performing well.

The launch of the respiratory syncytial virus vaccine Arexvy is going well, judging by 2023’s sales tally of £1.2bn, which is already 4pc of the group total.

That nicely supplements the £3.4bn revenues from shingles vaccine Shingrix and helps the company to get over its embarrassing failure to match Pfizer, Moderna and AstraZeneca in the race to find a Covid vaccine.

GSK now has 71 vaccines and speciality medicines in its drug development pipeline, including 18 at the Phase III stage, and is hoping for a dozen to come to market from 2025 onwards in areas such as HIV, oncology and respiratory conditions.


This roadmap presumably underpins the upgrade to medium-term sales and profits growth targets offered by chief executive Dame Emma Walmsley alongside the full-year figures.

GSK now expects compound annual growth rates of 7pc in revenues and 11pc in earnings between 2021 and 2026. Such a rate of progress would suggest that a multiple of barely 12 times forecast earnings looks decent value, especially when it is supported by a yield of 3.6pc, based on management’s guidance for a 60p-a-share dividend in 2024.

GSK still looks like good value. Hold."
Posted at 16/1/2024 13:58 by zho
And some more from Shore's Sean Conroy:

"Pre-trial hearings on the admissibility of expert testimony are scheduled on 22-25 Jan and should serve as an important indicator as to whether GSK is likely to make further settlements in 2024," Conroy said.

However, he added: "As a reminder, the analogous Daubert hearings in the federal-level multi-district litigation ruled in favour of GSK (and other manufacturers) and resulted in the outright, robust dismissal of all MDL cases given the lack of credible scientific evidence."

Conroy said that a worst-case scenario, in which Zantaz litigation costs GSK a total of $30.0bn, is currently being reflected in the share price. "[We] highlight any further clarity could support a material rerating of share; we have updated our sensitivity analysis and believe there remains a compelling risk-reward profile ahead of further updates on Zantac," he said.

The broker has lifted its target price from 1,850.0p to 2,000.0p and kept a 'buy' rating.
Posted at 11/1/2024 10:11 by anhar
MHRANGOON is correct that you have to adjust for the consolidation in order to compare current values with the pre-demerger value. You can't just look at the share prices alone to make a comparison with the pre-demerger value, you need to consider the number of shares involved.

The terms were that pre-demerger GSK holders received 1 HLN for every 1 GSK share held. Following that, GSK shares were consolidated at 4 for 5.

So assume for example you held 1,000 old GSK, then you would now have 1,000 HLN and 800 current GSK.

Using the above figures, the old GSK share price of 1,800p gives a value of £18,000 pre-dem.

With new GSK now at 1,570p the holding is worth £12,560 and HLN £3,370, a total of £15,930 which is a loss of £2,070 or 11.5% on the old GSK value. Clearly then, the combined holding would have to rise to £18,000 just to break even, which could be satisfied by GSK or HLN alone or some combination of the two.
Posted at 10/1/2024 18:17 by laurence llewelyn binliner
The pre split share price in summer 2022 was about 1800, and with the share price today at 1570, plus the HLN share price of 337 gives us c1900 total, so we are ahead again at last 18 months later..

GSK at 1800 stand alone would be great to see with HLN alongside adding value for those holders who kept them, as soon as they hit their debt to EBITDA ratio the dividend will pick up pace there too..
Posted at 03/1/2024 10:55 by patientcapital
GSK: Stock price offers attractive risk remuneration, according to Jefferies -- Market TalkSource: MF Dow Jones (English)Original article published in Dow Jones English Newswire, translated by Il Sole 24 Ore Radiocor editorial staff.(Il Sole 24 Ore Radiocor Plus) - Milan, 3 Jan - ? GSK is expected to give at least one-digit EPS growth guidance for 2024 and resolve the Zantac litigation case within the next few months, Jefferies analysts write in a note raising the rating on the buy-to-hold stock.Analysts estimate the pharmaceutical company will pay between $3 billion and $4 billion to resolve the case.The company's growth profile is undervalued and the current share price offers an attractive risk remuneration.Jefferies raised the stock's target price to 1,900 pence from 1,550 pence. Stocks are currently up 2.2% and 4.3% in the last 12 months. (ian.walker@wsj.com.)(END) Dow Jones NewswiresJanuary 03, 2024 03:50 ET (08:50 GMT)Copyright (c) 2024 Dow Jones-Radiocor
Posted at 15/11/2023 09:37 by abdullla
GSK share price going against the rise in the Ftse,getting ready for the double drop tomorrow due to X-div
Posted at 17/10/2023 13:40 by anhar
Correct TM. GSK is an outstanding example of all those styles:

Growth - after about a million years of holding, I'm up just 12.6% on original cost. This includes my HLN demerger shares. Not that I'm a growth player but that's the fact. Failed.

Income - This is my style. Divis were static for eight years at 80p for old GSK from 2014-2021 though admittedly there was a 20p special back in 2016. Following that payout paralysis, after the demerger the combined divis from new GSK and HLN were slashed. Failed.

Value - hard to see that GSK is underpriced with all that debt. Net debt at 30/6/23 was £18bn against net assets of £12bn and NAV is most certainly not above the share price. Failed.

So indeed GSK has something to offer these three approaches and it's ultra reliable. It fails all three.
Posted at 29/8/2023 09:23 by anhar
POR: What slashed divi?

Afaiaa, the divi was adjusted to take into account the recent splitting off of HLN. Add the two divis together and they probably add up to the pre-split gsk divi. Not 100% sure, but in any case, no one sensible would say the divi has been 'slashed', imv. If you can't stand the heat etc. Oh, you already have left the kitchen.

I think you are referring to another reader, I have not left but as a long term hold divi investor continue to retain both GSK and HLN. But the slashed divi comment was mine. I suggest you should check before referring to factual matters because I think you are wrong.

Here's why
old GSK 2021 divi 80.00p
new GSK 2022 divi 57.75p

HLN 2022 divi 2.4p

Thus the total for the two for 2022 of 60.15p is below the old GSK 80p for 2021 by 24.8%. I'd call that slashed and so you are incorrect to claim that they "probably add up to the pre-split gsk divi" or that "no one sensible would say the divi has been 'slashed', imv."

Another way to look at it, which avoids the potential distortions of the share adjustments, is not at the divis per share but to compare the total cash income received by an investor like me who continued to hold throughout the demerger, with no voluntary shareholding changes. Without a doubt my income has been "slashed".

HLN paid only the final divi for 2022 and will likely pay both an interim and final for 2023 but it remains very unlikely that even then, the total income from both for 2023 will match that from old GSK for 2021.
Gsk share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com